Related references
Note: Only part of the references are listed.Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects
Ying Zhang et al.
DEVELOPMENTAL BIOLOGY (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2009)
Semaphorin 3E Expression Correlates Inversely with Plexin D1 During Tumor Progression
Ilse Roodink et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
An Claes et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells
Boaz Kigel et al.
PLOS ONE (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1
Toshihiko Toyofuku et al.
EMBO JOURNAL (2007)
ανβ3 Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide
Ingrid Dijkgraaf et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression
Ilse Roodink et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Tumours can adapt to anti-angiogenic therapy depending on the stromal context: Lessons from endothelial cell biology
LCL van Kempen et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2006)
Plexin D1 expression is induced on tumor vasculature and tumor cells: A novel target for diagnosis and therapy?
I Roodink et al.
CANCER RESEARCH (2005)
Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins
A Dienst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast
H Kuroda et al.
VIRCHOWS ARCHIV (2005)
Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development
H Fujisawa
JOURNAL OF NEUROBIOLOGY (2004)
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives
ME Eichhorn et al.
DRUG RESISTANCE UPDATES (2004)
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option
WPJ Leenders et al.
CLINICAL CANCER RESEARCH (2004)
Semaphorin-plexin signaling guides patterning of the developing vasculature
J Torres-Vázquez et al.
DEVELOPMENTAL CELL (2004)
The sema domain
E Gherardi et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2004)
PlexinD1 and semaphorin signaling are required in endothelial cells for cadiovascular development
AD Gitler et al.
DEVELOPMENTAL CELL (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in Gd-DTPA-enhanced MRI.
W Leenders et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
The role of angiogenesis in vulvar cancer, vulvar intraepithelial neoplasia, and vulvar lichen sclerosus as determined by microvessel density analysis
J Saravanamuthu et al.
GYNECOLOGIC ONCOLOGY (2003)
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
JA Joyce et al.
CANCER CELL (2003)
Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study
AJ Schraa et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
P Castellani et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis
B Van Der Zwaag et al.
DEVELOPMENTAL DYNAMICS (2002)
Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance
B Döme et al.
JOURNAL OF PATHOLOGY (2002)
In vivo phage display and vascular heterogeneity:: implications for targeted medicine
M Trepel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2002)
Angiogenesis occurs by vessel elongation in proliferative phase human endometrium
LS Gambino et al.
HUMAN REPRODUCTION (2002)
Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia
PB Vermeulen et al.
JOURNAL OF PATHOLOGY (2001)
Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A
B Rohm et al.
MECHANISMS OF DEVELOPMENT (2000)
Share Paper
